Phosphate Therapeutics Selects CRO Clinipace to Manage Phase 2 Renal Study
Phosphate Therapeutics has selected CRO Clinipace Worldwide to manage a Phase II trial in its late-stage nephrology program.
Archives for February 13, 2014
Counterfeiting
DOJ prosecutor: is there a way to secure APIs from counterfeiters?
A US attorney who worked with Pfizer, Lilly and Merck to jail drug counterfeiters says cutting off criminal access to active pharmaceutical ingredients (APIs) is key.
Lack of Quality Unit equals US FDA Warning for Hong Kong API firm
A Hong Kong API distributor has received a Warning Letter from the US FDA after failing to have a Quality Unit and incorrectly labelling products.
Quintiles to run Phase I diabetes trial for Kareus
Kareus Therapeutics announced Wednesday that the US FDA has approved its Phase I clinical trial, which will be run by CRO Quintiles.
Catalent to increase workforce by two thirds at Kansas City plant
Catalent says it is adding 230 jobs at a Missouri plant recently earmarked for expansion.
Hospira confident 'swamp is drained' as US FDA ups status of Rocky Mount
The US FDA has upgraded Hospira’s troubled Rocky Mount, North Carolina plant to VAI (voluntary action indicated) status though its 2010 Warning Letter still stands.
Chiltern Partners With Karolinska Development in Sweden
CRO Chiltern International has partnered with Karolinska Development in Sweden, a life science investment company developing 21 drugs.